Literature DB >> 19099439

Synthesis, spectroscopy and structure of the parent furoxan (HCNO)2.

Tibor Pasinszki1, Balázs Havasi, Balázs Hajgató, Nicholas P C Westwood.   

Abstract

The parent furoxan (1,2,5-oxadiazole 2-oxide), synthesized from glyoxime and NO(2)(g), has been investigated in the gas phase for the first time by mid-infrared and He I photoelectron spectroscopy, and in the liquid phase by Raman spectroscopy. The ground-state geometry has been obtained from quantum-chemical calculations at the B3LYP, MPn (n = 2-4), CISD, QCISD, CCSD, CCSD(T), RSPTn (n = 2,3), MRCI, and MR-AQCC levels using 6-311++G(2d,2p), cc-pVTZ, aug-cc-pVTZ, cc-pCVTZ, and cc-pVQZ basis sets. Furoxan is predicted to be planar, with a strong exocyclic and a relatively weak endocyclic N-O bond. The furoxan moiety is electron rich, indicated e.g. by a large negative NPA charge (-0.46 e). According to various aromaticity indices, furoxan is nearly as aromatic as furan and furazan. Unlike alkyl- and cyano-substituted furoxans, the parent furoxan, upon thermolysis, does not cleave to the monomer nitrile oxide, yielding only HNCO, HCN, CO(2), CO, NO, and H(2)O decomposition products.

Entities:  

Year:  2009        PMID: 19099439     DOI: 10.1021/jp810066r

Source DB:  PubMed          Journal:  J Phys Chem A        ISSN: 1089-5639            Impact factor:   2.781


  2 in total

1.  In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats.

Authors:  Adam B Pippin; Zaira Hidayah Mohd Arshad; Ronald J Voll; Jonathon A Nye; Sussan Ghassabian; Craig M Williams; Alessandra Mancini; Dennis C Liotta; Maree T Smith; Mark M Goodman
Journal:  ACS Med Chem Lett       Date:  2016-03-30       Impact factor: 4.345

2.  Theoretical study on the structure and stability of [1,2,5] oxadiazolo [3,4-e] [1,2,3,4]-tetrazine-4,6-Di-N-dioxide (FTDO).

Authors:  Wei-Peng Lai; Peng Lian; Tao Yu; Jian-Hua Bu; Ying-Zhe Liu; Wei-Liang Zhu; Jian Lv; Zhong-Xue GE
Journal:  J Mol Model       Date:  2014-07-01       Impact factor: 1.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.